Coverage depends on the indication
Insurance coverage for GLP-1 receptor agonists varies enormously by what they're prescribed for. The four FDA-approved indications break out very differently:
• Type 2 diabetes (Ozempic, Mounjaro): broadly covered, often as a preferred second-line agent after metformin. Prior authorization is common but routinely approved. • Chronic weight management (Wegovy, Zepbound, Saxenda): coverage is highly variable. Many commercial plans explicitly exclude weight-loss medications; many state Medicaid programs do not cover them; Medicare does not currently cover them for weight management alone. • Cardiovascular risk reduction (Wegovy): since the March 2024 label expansion, coverage has improved for the secondary-prevention population (established CVD + obesity), often through clinical-policy alignment with statin coverage. • Obstructive sleep apnea (Zepbound, approved December 2024): coverage frameworks are still being built; expect prior-authorization complexity through 2026.
How to read your benefits
Look in your plan documents for these terms: 'anti-obesity medications' (often explicitly excluded), 'weight-loss drugs' (often excluded), 'GLP-1 receptor agonists for type 2 diabetes' (often covered with PA). The presence or absence of an explicit weight-loss exclusion is the most important signal.
If your plan covers weight-loss medications, expect prior authorization that typically requires documented BMI ≥ 30 (or BMI ≥ 27 with a weight-related comorbidity), and often documented prior attempts at lifestyle modification.
When compounded is the bridge
Compounded GLP-1s through telehealth programs are by definition cash-pay — insurance does not reimburse for compounded preparations. The compounded route is most useful as a bridge in two specific situations: (1) you have no coverage for weight-loss medications and brand-name cost is prohibitive; (2) you have a documented allergy to an excipient in the brand-name product where compounded preparation can substitute.
For patients with strong coverage for brand-name GLP-1s under a diabetes or CV-risk indication, compounded routes are rarely the right answer.
Manufacturer cash-pay programs
Eli Lilly's LillyDirect program offers reduced cash-pay pricing on tirzepatide single-dose vials, typically $399–$599/month depending on dose. Novo Nordisk has historically maintained narrower cash-pay programs.
These sit between brand-name list pricing and compounded pricing, with the advantage of being authentic FDA-approved product. For patients who can stretch to that price band, they're often the right answer.